Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)
dc.contributor.author | Garassino, MC | |
dc.contributor.author | Paz-Ares, L | |
dc.contributor.author | Hui, R | |
dc.contributor.author | Faivre-Finn, Corinne | |
dc.contributor.author | Spira, A | |
dc.contributor.author | Planchard, D | |
dc.contributor.author | Ozguroglu, M | |
dc.contributor.author | Daniel, DB | |
dc.contributor.author | Vicente, D | |
dc.contributor.author | Murakami, S | |
dc.contributor.author | Ryden, A | |
dc.contributor.author | Zhang, Y | |
dc.contributor.author | O'Brien, C | |
dc.contributor.author | Dennis, PA | |
dc.contributor.author | Antonia, SJ | |
dc.date.accessioned | 2020-03-27T09:27:59Z | |
dc.date.available | 2020-03-27T09:27:59Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, et al. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Ann Oncol. 2019;30 Suppl 2:ii78. | en |
dc.identifier.pmid | 32131355 | en |
dc.identifier.doi | 10.1093/annonc/mdz094.001 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622822 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdz094.001 | en |
dc.title | Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Thoracic Unit, Fondazione IRMedical Oncology, University Hospital 12 de Octubre, Madrid, Spain | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-03-30T13:21:34Z |